Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
Pursuant to Section § 28a of the Danish Act on Securities Trading, Bavarian
Nordic A/S shall make public transactions of shares and related securities of
Bavarian Nordic A/S by persons holding managerial responsibilities and/or
persons/companies closely associated with such.
Asger Aamund, Chairman of the Board of Bavarian Nordic, has notified Bavarian
Nordic, that his company, A.J. Aamund A/S today has sold 890,000 preemptive
rights. Subsequently, A.J. Aamund A/S holds 444,099 preemptive rights, which
allow for the subscription of 222,049 new shares under the ongoing rights issue.
As previously announced, A.J. Aamund A/S will participate in the rights issue on
a cash-neutral basis (after transaction costs), and thus will subscribe for
222.049 new shares of DKK 80, totalling a market value of DKK 17,763,920.00.
Name A. J. Aamund A/S
Reason for transaction Closely related to Asger Aamund, Chairman of the Board
of Bavarian Nordic A/S
Issuer Bavarian Nordic A/S
ID code/ISIN DK0060205268
Description Preemptive rights
Transaction Sale
Trading date 14 January 2010
Market NASDAQ OMX Copenhagen
Number 890,000
Market value (DKK) 17,800,000.00
Contact
Anders Hedegaard, President & CEO. Phone +45 23 20 30 64
Not for release, publication or distribution, directly or indirectly in or into
Australia, Canada, Japan or the United States
This announcement does not constitute or form part of an offer to sell or the
solicitation of an offer to buy the securities of Bavarian Nordic A/S (the
"Securities") in Australia, Canada, Japan or the United States or in any other
jurisdiction. The Securities may not be offered or sold in the United States
absent registration or an exemption from registration under the U.S. Securities
Act of 1933, as amended. The issuer of the Securities has not registered, and
does not intend to register, any portion of the Offering in the United States or
in any jurisdiction outside Denmark and the United Kingdom, and does not intend
to conduct a public offering of the Securities in the United States or in any
jurisdiction outside Denmark and the United Kingdom. Copies of this announcement
are not being made and may not be distributed or sent into Australia, Canada,
Japan or the United States.
Forward-looking statements
This announcement includes "forward-looking statements" that involve risks,
uncertainties and other factors, many of which are outside of our control that
could cause actual results to differ materially from the results discussed in
the forward-looking statements. Forward-looking statements include statements
concerning our plans, objectives, goals, future events, performance and/or other
information that is not historical information. We undertake no obligation to
publicly update or revise forward-looking statements to reflect subsequent
events or circumstances after the date made, except as required by law.
About Bavarian Nordic
Bavarian Nordic A/S is a leading industrial biotechnology company developing and
producing novel vaccines for the treatment and prevention of life-threatening
diseases with a large unmet medical need. The company's pipeline is focused in
the three areas; biodefence, cancer and infectious diseases, and includes seven
development programmes. Two programmes are under preparation for Phase III:
IMVAMUNE®, a third-generation smallpox vaccine is being developed under a
contract with the US government, and PROSTVAC(TM), a therapeutic vaccine for
advanced prostate cancer is being developed under a collaboration agreement with
the National Cancer Institute.
Bavarian Nordic is listed on NASDAQ OMX Copenhagen under the symbol BAVA.
For more information please visit www.bavarian-nordic.com
[HUG#1373538]
